DNA Hormones is a comprehensive nutrigenetic test analysing and reporting on metabolism and detoxification of sex hormones. It is designed to assist in the management of hormone-related conditions, affecting both men and women. DNA Hormones is essentially an upgrade to the DNA Oestrogen test.
The DNA Hormones test analyses and reports on gene variants that have been shown to have an impact on sex steroid metabolism and biotransformation, affecting male and female health.
The test is suitable for those who are suffering from, or have a family history of, any hormone related disorder or experiencing symptoms that might be related to imbalanced hormone metabolism. Hormone related disorders include endometriosis and polycystic ovarian syndrome (PCOS), (sub)fertility, earlier onset of, and heightened symptoms in menopause, bone health disorders, thrombosis, as well as breast, ovarian and prostate cancer.
It is also beneficial for anyone taking/considering hormone therapy (contraceptive or replacement therapy) for insights into potential clotting risk and to ensure detoxification pathways are optimally supported.
An imbalance in hormone production can affect a wide range of body functions, producing symptoms that negatively affect the quality of life and may increase the risk for hormone-related conditions.
Research has shown that hormonal imbalances can occur due to an increased lifetime exposure to an unsuitable environment (e.g. high oestrogen exposure, increased BMI, carcinogens, sedentary behaviour). This, together with an intrinsic imbalance, due to genetic variation, is a strong risk factor for the development of various hormone-related conditions, affecting both men and women. Depending on the stage in an individual’s lifecycle, environmental exposures and genetic variants carried, certain hormonal biosynthesis, degradation and biotransformation pathways might be preferred. This increases risk for altered sex hormone metabolite ratios as well as imbalance in redox status. These alterations have been linked to predisposition for hormone related disorders including endometriosis and polycystic ovarian syndrome (PCOS), (sub)fertility, earlier onset of, and heightened symptoms in menopause, bone health disorders, thrombosis, as well as breast, ovarian and prostate cancer. The identification and targeted treatment of hormonal imbalances using personalised interventions, based on the patients’ genetic information, can assist in the management of hormone-related symptoms, reduce their risk for hormone-related diseases and improve their quality of life.
The report offers personalised diet, lifestyle and hormone interventions to support relevant pathways and help you achieve and maintain optimal hormonal health and resilience and extended healthspan.
Test type:
The test is suitable for those who are suffering from, or have a family history of, any hormone related disorder or experiencing symptoms that might be related to imbalanced hormone metabolism. Hormone related disorders include endometriosis and polycystic ovarian syndrome (PCOS), (sub)fertility, earlier onset of, and heightened symptoms in menopause, bone health disorders, thrombosis, as well as breast, ovarian and prostate cancer.
It is also beneficial for anyone taking/considering hormone therapy (contraceptive or replacement therapy) for insights into potential clotting risk and to ensure detoxification pathways are optimally supported.
Sample required:
Bloodspot
Average processing time:
18-21 days
The report provides
- Gene, and genotype-specific information that is evidence based and clinically relevant
- Impact of the gene variant on disease risk and how it affects enzyme function
- A comprehensive overview of sex hormone metabolism and detoxification pathways – personalised to the patient, based on their genotype
- Insights into the functioning of sex-hormone pathways based on genetic variation carried
- The identification and targeted treatment of hormonal imbalances using personalised interventions, based on the patients’ genetic information
- Guidance in the management of hormone-related symptoms, reducing risk for hormone-related diseases and improving quality of life.
Assessment of
21 genetic variants involved in:
- Steroidogenesis – Androgen, progestogen and estrogen metabolism
- Binding and transport
- Phase I and phase II detoxification
- Clotting risk
Tests for:
Genotype impact on enzyme function and the resulting metabolite in the hormone pathway, together with related phenotypes and gene-environment interactions.
Analytes measured:
21 SNPs reported
| Biological area | Gene |
| Steroidogenesis | CYP11A1 CYP17A CYP19A1 HSD3B1 |
| Binding & transport | SHBG SLCO1B1 |
| Phase 1 detoxification | CYP1A1 CYP1A1 CYP1B1 CYP3A4 |
| Phase II detoxification | UGT2B15 UGT2B17 COMT MTHFR NQ01 MnSOD GSTM1 GSTT1 SULT1A1 |
| Clotting risk | FACTOR II FACTOR V |
